摘要
目的探讨尼妥珠单抗注射液联合替吉奥治疗复发鼻咽癌患者的临床疗效。方法回顾性分析本院2018年2月至2019年6月收治的85例复发鼻咽癌患者的临床资料,根据不同药物治疗方案分为对照组(基础治疗+替吉奥,n=42)与观察组(基础治疗+尼妥珠单抗+替吉奥,n=43)。比较两组近期疗效、生存质量及不良反应情况。结果观察组总缓解率为55.81%,明显高于对照组的30.95%,差异有统计学意义(P<0.05);治疗后,两组鼻咽癌患者生存质量量表(QOL-NPC)评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义。结论尼妥珠单抗联合替吉奥治疗复发鼻咽癌患者,可提高近期疗效和患者生存质量,且不增加不良反应。
Objective To investigate the clinical efficacy of nituzumab injection combined with ticgio in the treatment of patients with recurrent nasopharyngeal carcinoma.Methods The clinical data of 85 patients with recurrent nasopharyngeal carcinoma treated in our hospital from February 2018 to June 2019 were retrospectively analyzed,and they were divided into control group(basic treatment+ticgio,n=42)and observation group(basic treatment+nituzumab+ticgio,n=43)according to different drug treatment regiments.The short-term efficacy,quality of life and adverse reactions were compared between the two groups.Results The total remission rate of observation group was 55.81%,which was significantly higher than that of control group(30.95%),the difference was statistically significant(P<0.05).After treatment,the quality of life scale(QOL-NPC)scores of NPC patients between two groups were higher than before treatment,and the observation group was higher than the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Nituzumab combined with ticgio in the treatment of patients with recurrent nasopharyngeal carcinoma can improve the short-term efficacy,improve the quality of life of patients,and do not increase the adverse reactions.
作者
钟琼
ZHONG Qiong(Department of Oncology,Ganzhou People's Hospital of Jiangxi Province,Ganzhou,Jiangxi,341000,China)
出处
《当代医学》
2021年第14期12-14,共3页
Contemporary Medicine
基金
赣州市科技局计划项目(GZ2018ZSF304)。
关键词
复发鼻咽癌
尼妥珠单抗
替吉奥
Recurrent nasopharyngeal carcinoma
Nituzumab
Ticgio
